预约演示

更新于：2026-03-25

Carbidopa/Levodopa

卡比多巴/左旋多巴

更新于：2026-03-25

概要

基本信息

药物类型

小分子化药

别名

AP-CD/LD、AP-CDLD、Carbidopa and Levodopa

+ [70]

靶点

DDC x DRDs

作用方式

抑制剂、拮抗剂

作用机制

DDC抑制剂(DOPA脱羧酶抑制剂)、DRDs拮抗剂(多巴胺受体家族拮抗剂)

治疗领域

神经系统疾病内分泌与代谢疾病其他疾病

在研适应症

帕金森障碍帕金森病脑炎后帕金森病+ [5]

非在研适应症

并发症安定药恶性综合征精神运动性激动

原研机构

Merck & Co., Inc.

在研机构

上海汉都医药科技有限公司

Impax Laboratories LLC

Kyowa Pharmaceutical Industry Co., Ltd.

+ [24]

非在研机构

Organon Pharmaceuticals USA, Inc.Amneal Pharma Europe Ltd.

汉都医药

+ [2]

权益机构

Amneal Intermediate, Inc.

Navamedic ASA

Contera Pharma ApS

+ [7]

最高研发阶段批准上市

首次获批日期

美国 (1975-05-02),

脑炎后帕金森病继发性帕金森病帕金森病

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、快速通道 (美国)

登录后查看时间轴

关联

182

项与卡比多巴/左旋多巴相关的临床试验

NCT07442591

/ Not yet recruiting临床1期

A Clinical Study to Assess the Effect of Different Dosing Intervals on the Multiple-Dose Pharmacokinetics of WD-1603 (25mg Carbidopa/150mg Levodopa) When Administered Before Meals in Healthy Participants

WD-1603 contains two different drugs called levodopa and carbidopa in one tablet. The goal of this clinical trial is to see if taking the study drug WD-1603 at different time intervals affects how the drug acts in healthy volunteers. We also want to learn about the safety of WD-1603.
The main question we want to answer is:
* How does the body process WD-1603 when it is taken by different time intervals? What will participants do?
* Participants will take one tablet of WD-1603 twice a day on three separate days.
* On each dosing day, the two doses will be spaced different hours apart.
* Between each dosing day, there will be a rest period of up to 7 days.

开始日期2026-03-01

申办/合作机构

上海汉都医药科技有限公司

[+2]

NCT07246278

/ Recruiting临床1/2期IIT

Evaluating Safety and Efficacy of Celecoxib in Patients With PD.

Parkinson's disease (PD) is a chronic neurodegenerative disease clinically characterized by bradykinesia, hypokinesia, rigidity, resting tremor, and postural instability. These motor manifestations are attributed to the degeneration and selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), leading to a dopamine (DA) deficiency in the striatum. Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD

开始日期2025-11-20

申办/合作机构

Tanta University

NCT07229664

/ Recruiting临床2/3期IIT

Clinical Study to Evaluate Safety and Effectiveness of Vinpocetine in Patients With Parkinsonian Disease

The clinical manifestations of Parkinson's disease (PD), a chronic neurodegenerative condition, include resting tremor, hypokinesia, bradykinesia, stiffness and postural instability. These motor symptoms are caused by a selective loss and degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) region, which leads to a dopamine (DA) insufficiency in the striatum

开始日期2025-11-10

申办/合作机构

Tanta University

100 项与卡比多巴/左旋多巴相关的临床结果

登录后查看更多信息

100 项与卡比多巴/左旋多巴相关的转化医学

登录后查看更多信息

100 项与卡比多巴/左旋多巴相关的专利（医药）

登录后查看更多信息

730

项与卡比多巴/左旋多巴相关的文献（医药）

2026-03-01·PARKINSONISM & RELATED DISORDERS

Comparative pharmacokinetics of levodopa–carbidopa intestinal gel infusion and foslevodopa–foscarbidopa continuous subcutaneous infusion therapies in advanced Parkinson's disease

Article

作者: Oda, Shinji ; Hama, Yuka ; Inagawa, Shoya ; Takahashi, Yuji ; Namatame, Shuho ; Mukai, Yohei ; Okumura, Motohiro ; Takizawa, Hotake ; Shinmi, Jun ; Yamakawa, Toru ; Takei, Junko ; Nomoto, Juri ; Ishihara, Tasuku ; Furukawa, Fumiko

INTRODUCTION:

Levodopa-carbidopa intestinal gel therapy (LCIG) and foslevodopa-foscarbidopa continuous subcutaneous infusion therapy (FOCS) are device-aided therapies for advanced Parkinson's disease. Comparative real-world pharmacokinetic (PK) data remain limited. This study aimed to compare overall plasma levodopa exposure between LCIG and FOCS.

METHODS:

Patients who initiated LCIG or FOCS, completed dose optimization, and underwent a standardized levodopa challenge were evaluated. Plasma levodopa concentrations and motor states were assessed repeatedly over 420 min. Overall concentrations were compared using a linear mixed-effects model. Steady-state concentration (SSConc; 300-420 min) and its relationship with body-surface-area-adjusted infusion rate were examined. Time to On and the plasma concentration at On transition (On-Conc) were analyzed.

RESULTS:

Mean plasma levodopa concentrations tended to be higher with FOCS, although the group effect was not significant (geometric mean ratio: 1.38; p = 0.060). SSConc was higher with FOCS (12.85 ± 2.78 vs. 9.23 ± 1.61 nmol/mL). Both therapies showed linear SSConc-dose relationships, with a steeper slope for FOCS. LCIG produced a faster transition to the On state (median 45 vs. 150 min), whereas On-Conc was similar between groups (approximately 10 nmol/mL). In the FOCS group, baseline Off occurred only when nighttime infusion rates were ≤74 % of daytime rates.

CONCLUSION:

LCIG and FOCS show distinct PK profiles despite similar overall concentrations. LCIG provides a rapid rise in levodopa levels and earlier On onset, whereas FOCS yields higher SSConc values and greater dose-concentration efficiency, informing titration approaches, nighttime infusion settings, and individualized selection of continuous infusion-based dopaminergic therapy.

2026-02-01·JOURNAL OF NEURAL TRANSMISSION

Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations

Article

作者: Urban, Peter Paul ; Dresel, Christian ; Kassubek, Jan ; Müller, Rahel ; Koeglsperger, Thomas ; Paus, Sebastian ; Oehlwein, Christian ; Berberovic, Emir ; Haferkamp, Sebastian

Abstract:

Traditional advanced therapies in Parkinson’s disease (PD) with motor fluctuations and dyskinesias like continuous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel (LCIG), levodopa-carbidopa entacapone intestinal gel (LECIG), or deep brain stimulation (DBS) have played a central role in managing therapy-related complications. Recently, continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) has emerged as a novel therapeutic option. This manuscript provides insights from one year of real-world experience with CSFLI, addressing critical questions that clinicians face when selecting the most appropriate therapy for advanced PD. Our discussion centers on key considerations for patient selection, exploring which individuals may benefit more from CSFLI compared to other device-aided therapies. We highlight CSFLI’s advantages in flexibility and ease of use but also consider limitations, particularly its side effects, such as skin-related issues. Recommendations are presented on how to prevent and manage these adverse effects to maximize patient compliance and therapeutic success. Additionally, the paper examines strategies for optimizing concurrent oral medications when combined with CSFLI, providing guidance on balancing pump infusion with necessary adjunctive oral treatments.

2026-02-01·Movement Disorders Clinical Practice

Switching from Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Carbidopa Infusion in Advanced Parkinson's Disease: A Case Series

Article

作者: Brandel, Jean‐Philippe ; Baille, Guillaume ; de Saint‐Vaulry, Hélène ; Patte‐Karsenti, Nathalie ; Desjardins, Clément ; Salardaine, Quentin

Abstract:

Background:

Continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) is a novel non‐surgical alternative to levodopa/carbidopa intestinal gel (LCIG) for advanced Parkinson's disease (aPD), but real‐world switch data remain limited.

Objectives:

To describe the feasibility, safety, and clinical effects of switching from LCIG to CSFLI.

Methods:

We retrospectively reviewed eight aPD patients switched from LCIG to CSFLI at a single center between November 2024 and May 2025. Motor and non‐motor symptoms, quality of life, and levodopa equivalent daily doses were assessed at baseline (M0) and six months (M6).

Results:

Small but significant improvements occurred in UPDRS part I, III, and IV and PDQ‐8 scores at M6. Total LEDD remained stable. CSFLI was well tolerated with mild local skin reactions.

Conclusion:

Switching from LCIG to CSFLI is feasible and safe, providing stable dopaminergic delivery with modest symptomatic benefits in selected aPD patients.

340

项与卡比多巴/左旋多巴相关的新闻（医药）

2026-03-23

·FiercePharma

FDA mandates label updates to common Parkinson's meds based on seizure risk finding

In its safety review, the FDA found 14 causes of seizures linked to vitamin B6 deficiency in patients taking the common Parkinson’s disease drugs. A common drug combo for Parkinson’s disease will require a new FDA warning after the agency flagged 14 cases of seizures in patients using the medications. The agency is mandating (PDF) that drugmakers marketing products incorporating levodopa and carbidopa update their prescribing information to note that the drugs can cause vitamin B6 deficiency and vitamin B6 deficiency-associated seizures. Healthcare providers should evaluate patients’ baseline vitamin B6 levels prior to and during treatment and supplement patients with the vitamin as necessary, the warning says.The label update affects Amneal’s Crexont and Rytary; Avion Pharmaceuticals’ Dhivy; Merck’s Sinemet and controlled-release Sinemet CR; Novartis’ Stalevo; and AbbVie’s Duopa. Also affected is AbbVie’s newer Vyalev, a subcutaneous treatment that delivers prodrugs of carbidopa and levodopa via an infusion pump system. Vyalev’s ingredients of foscarbidopa and foslevodopa are drug derivatives of carbidopa and levodopa that become active after entering the body. Parkinson’s disease has been linked to dopamine deficiency, making levodopa, a metabolic precursor to dopamine, a favored treatment approach dating back to the 1960s. However, the drug must be taken with another medication to prevent it from breaking down in the bloodstream before crossing the blood-brain barrier, making the combo of carbidopa and levodopa the reigning standard-of-care in Parkinson’s disease treatment.But as levodopa converts to dopamine, crucial vitamin B6 levels can be impacted, the FDA pointed out in its warning. Carbidopa also binds to the active form of the vitamin, which can further drive down vitamin B6 levels. In its safety review, the FDA identified 14 causes of seizures linked to vitamin B6 deficiency in patients taking the common Parkinson’s disease drugs, including 13 instances that were submitted to the FDA’s adverse events reporting system and 1 reported in medical literature. There are “likely additional cases about which we were unaware,” the agency notes. Each of the reviewed cases involved levodopa doses greater than 1,000 mg daily and the seizures were split across oral formulations of the drugs and an enteral suspension. AbbVie makes the enteral suspension version with its Duopa, a gel medication that’s delivered directly into the small intestine through a tube. Some of the cases progressed to status epilepticus, a longer-lasting seizure that can cause brain damage or death, the FDA added. Several of the seizure reports showed “clinical evidence supportive of vitamin B6 deficiency,” and nine seizures were resolved when treated with supplemental vitamin B6. Two deaths occurred in patients with “documented low vitamin B6 levels and poorly controlled seizures,” according to the agency. “Based on the available data, FDA concluded there is reasonable evidence of a causal association between drug products containing carbidopa/levodopa and vitamin B6 deficiency-associated seizures,” the FDA said.Although no seizures were confirmed to result from products containing carbidopa/levodopa and entacapone (Novartis’ Stalevo) and injectable versions of carbidopa/levodopa (AbbVie’s Vyalev), the FDA is slapping the same warning on those meds, considering a likely risk based on “biological plausibility” and clinical trial data from the meds. Vyalev was the most recently approved carbidopa/levodopa med, scoring its FDA nod in 2024. The drug is a follow-up to AbbVie’s landmark 2015 Duopa, which sparked a trend of delivery system innovation in the Parkinson’s space as manufacturers looked to avoid the short half-life associated with oral versions of the meds. The FDA safety sweep of carbidopa and levodopa meds could lend credence to Supernus Pharmaceuticals’ novel Parkinson’s disease approach with Onapgo, a wearable pump that delivers a continuous subcutaneous infusion of Supernus’ dopamine agonist apomorphine (Apokyn). After winning approval in 2025 following three FDA rejections, the drug made so much of a splash in the disease space that the company had to pause delivery to new patients in November based on “stronger than expected demand,” Supernus said.Onapgo’s shipments has since resumed and the drug collected $17.3 million in 2025 sales, while AbbVie’s Vyalev took home $482 million and its older Duopa garnered sales of $381 million.

上市批准临床结果

2026-03-23

·BioSpace

FDA Warns of Seizure Risk With Some Parkinson’s Drugs

iStock, undefined undefined The FDA detected 14 cases of vitamin B6 deficiency–linked seizures and two deaths in patients with Parkinson’s disease taking carbidopa/levodopa drugs. Both AbbVie and Novartis market levodopa-based products. Products containing levodopa and carbidopa, a common drug combination for treating Parkinson’s disease, could trigger seizures, the FDA has found. The agency conducted a safety review of drugs carrying these compounds and found 14 cases of seizures linked to vitamin B6 deficiency, according to a safety alert on Friday. In all of these cases, levodopa doses exceeded 1,000 mg per day. Seizures were typically focal-onset, meaning they started in a limited region of the brain. They then spread to include both hemispheres, leading to convulsions and causing emergencies in some cases. Two patients died, both of whom had had low vitamin B6 levels and poorly controlled seizures, the FDA said. Nine patients were given vitamin B6 supplementation, which in all cases led to the resolution of their seizures. All 14 cases of carbidopa/levodopa-linked seizures were detected through post-marketing surveillance or found in the medical literature, “so there are likely additional cases about which we are unaware,” the FDA said. While the safety signals arose in those taking oral formulations and enteral suspensions of carbidopa/levodopa, the regulator did not dismiss the possibility that other products—such as injectables or those that use additional compounds to enhance the original drug combo—could carry the same risk. “Biological plausibility suggests there may be a similar risk across all drug products containing carbidopa/levodopa,” the FDA wrote. The agency has already notified all manufacturers of drugs carrying carbidopa/levodopa, asking them to update the labels of their respective products to carry warnings for vitamin B6 deficiency-associated seizures. In the meantime, healthcare professionals should assess their patients’ vitamin B6 levels at baseline and throughout treatment, and consider supplementation as needed, the FDA recommended. Levodopa is a synthetic drug that, once it reaches the brain, is converted into dopamine, a neurotransmitter that is deficient in patients with Parkinson’s disease. Levodopa’s therapeutic benefits for Parkinson’s were first established in the 1960s, and the first drug that combined it with the decarboxylase inhibitor carbidopa—which improved its efficacy and safety—entered the market in 1975 . The combo remains in use today. In October 2024, the FDA approved AbbVie’s Vyalev , a levodopa-based therapy for advanced Parkinson’s disease. The product contains foscarbidopa and foslevodopa, prodrugs that can be given continuously over 24 hours as a subcutaneous infusion. Novartis also owns a carbidopa/levodopa product in Stalevo , which additionally uses entacapone to sustain heightened levels of the drug in the bloodstream. The industry is now opening up new therapeutic avenues for Parkinson’s disease, however. Eli Lilly in January scooped up Ventyx Biosciences for $1.2 billion, gaining access to a pipeline of drugs that target the NLRP3 inflammatory cascade, an underlying pathway driving the condition. Also looking at an immune-centered approach to Parkinson’s is AC Immune, which in December 2025 demonstrated slower disease progression in patients treated with its anti-alpha-synuclein therapy. Parkinson’s disease 5 Investigational Therapies That Could Change the Parkinson’s Landscape From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment. January 26, 2026 · 9 min read · Tristan Manalac Read more

上市批准临床结果

2026-03-22

·信狐药迅

本周所有仿制药上市申请均获通知书| 新获批(3.16-3.22）

每周药品注册获批数据，分门别类呈现，一目了然。(3.16-3.22）新药上市申请药品名称企业注册分类受理号伊托法替布软膏明慧医药(杭州)有限公司 1 CXHS2500058 新药临床申请药品名称企业注册分类受理号 HCXT-2001片上海瀚辰星泰医药科技有限公司 1 CXHL2600171 HCXT-2001片上海瀚辰星泰医药科技有限公司 1 CXHL2600170 KR23248胶囊江西科睿药业有限公司 1 CXHL2600180 HS-20152注射液上海翰森生物医药科技有限公司 1 CXHL2600052 HS-20138注射液上海翰森生物医药科技有限公司 1 CXHL2600045 QLS1317片上海齐鲁制药研究中心有限公司 1 CXHL2600057 QLS1317片上海齐鲁制药研究中心有限公司 1 CXHL2600056 BW-50218注射液上海舶望制药有限公司 1 CXHL2600050 HRS9531注射液福建盛迪医药有限公司 1 CXHL2600041 HRS9531注射液福建盛迪医药有限公司 1 CXHL2600040 HRS9531注射液福建盛迪医药有限公司 1 CXHL2600039 HS-10587片江苏豪森药业集团有限公司 1 CXHL2600038 HS-10587片江苏豪森药业集团有限公司 1 CXHL2600037 注射用TRD209 北京泰德制药股份有限公司 1 CXHL2600044 IN10028肠溶片应世生物科技(南京)有限公司 1 CXHL2600043 IN10028肠溶片应世生物科技(南京)有限公司 1 CXHL2600042 HS-10241片江苏豪森药业集团有限公司 1 CXHL2600026 HS-10241片江苏豪森药业集团有限公司 1 CXHL2600025 HS-10529胶囊江苏豪森药业集团有限公司 1 CXHL2600020 NTQ6179片南京正大天晴制药有限公司 1 CXHL2600015 NTQ6179片南京正大天晴制药有限公司 1 CXHL2600014 NTQ6179片南京正大天晴制药有限公司 1 CXHL2600013 SYH2082注射液北京抗创联生物制药技术研究有限公司 1 CXHL2600019 SYH2082注射液北京抗创联生物制药技术研究有限公司 1 CXHL2600018 FB7013注射液前沿生物药业(南京)股份有限公司 1 CXHL2501518 RC017眼膏南京瑞初医药有限公司 1 CXHL2501535 RC017眼膏南京瑞初医药有限公司 1 CXHL2501534 RC017眼膏南京瑞初医药有限公司 1 CXHL2501533 RAG-01注射液中美瑞康核酸技术(南通)研究院有限公司 1 CXHL2501497 注射用硼[10B]法仑华硼中子科技(杭州)有限公司 2.2 CXHL2600055 HS-10566植入剂江苏豪森药业集团有限公司 2.2 CXHL2600054 HS-10566植入剂江苏豪森药业集团有限公司 2.2 CXHL2600053 ZYG24012 江苏知原药业股份有限公司 2.2 CXHL2600049 TRD306凝胶北京泰德制药股份有限公司 2.2 CXHL2600048 TRD306凝胶北京泰德制药股份有限公司 2.2 CXHL2600047 TRD306凝胶北京泰德制药股份有限公司 2.2 CXHL2600046 盐酸尼卡地平控释片北京五和博澳药业股份有限公司 2.2 CXHL2501539 H008AMX片江苏柯菲平医药股份有限公司 2.3 CXHL2600012 西格列他钠二甲双胍缓释片深圳微芯生物科技股份有限公司 2.3 CXHL2600017 西格列他钠二甲双胍缓释片深圳微芯生物科技股份有限公司 2.3 CXHL2600016 SL-0044 上海则正医药科技股份有限公司 2.4 CXHL2600032 SL-0044 上海则正医药科技股份有限公司 2.4 CXHL2600031 SL-0044 上海则正医药科技股份有限公司 2.4 CXHL2600030 SL-0044 上海则正医药科技股份有限公司 2.4 CXHL2600029 SL-0044 上海则正医药科技股份有限公司 2.4 CXHL2600028 瑞加诺生注射液江西银涛药业股份有限公司 2.4 CXHL2501437 LVRNA015 珠海丽凡达生物技术有限公司 1.2 CXSL2501132 AK117注射液中山康方生物医药有限公司 1 CXSL2600065 AK117注射液中山康方生物医药有限公司 1 CXSL2600064 AK109注射液康融东方(广东)医药有限公司 1 CXSL2600063 注射用AK138D1 中山康方生物医药有限公司 1 CXSL2600062 注射用AK146D1 中山康方生物医药有限公司 1 CXSL2600061 TQB2922注射液正大天晴药业集团南京顺欣制药有限公司 1 CXSL2600059 TQB2922注射液正大天晴药业集团南京顺欣制药有限公司 1 CXSL2600058 重组人血小板源生长因子凝胶华芢生物科技(青岛)股份有限公司 1 CXSL2600042 重组人血小板源生长因子凝胶华芢生物科技(青岛)股份有限公司 1 CXSL2600039 重组人血小板源生长因子凝胶华芢生物科技(青岛)股份有限公司 1 CXSL2600037 SCTB41注射液神州细胞工程有限公司 1 CXSL2600035 重组人血小板源生长因子凝胶华芢生物科技(青岛)股份有限公司 1 CXSL2600041 重组人血小板源生长因子凝胶华芢生物科技(青岛)股份有限公司 1 CXSL2600038 重组人血小板源生长因子凝胶华芢生物科技(青岛)股份有限公司 1 CXSL2600040 SCTC21C注射液神州细胞工程有限公司 1 CXSL2600049 SAL0150片深圳信立泰药业股份有限公司 1 CXSL2600023 SAL0150片深圳信立泰药业股份有限公司 1 CXSL2600022 SAL0150片深圳信立泰药业股份有限公司 1 CXSL2600021 SAL0150片深圳信立泰药业股份有限公司 1 CXSL2600020 BL-ARC002注射液成都百利多特生物药业有限责任公司 1 CXSL2600019 CM336注射液康诺亚生物医药科技(成都)有限公司 1 CXSL2600044 CM336注射液康诺亚生物医药科技(成都)有限公司 1 CXSL2600043 SAL0150片深圳信立泰药业股份有限公司 1 CXSL2600032 SAL0150片深圳信立泰药业股份有限公司 1 CXSL2600031 SAL0150片深圳信立泰药业股份有限公司 1 CXSL2600030 SAL0150片深圳信立泰药业股份有限公司 1 CXSL2600029 SAL0150片深圳信立泰药业股份有限公司 1 CXSL2600028 SAL0150片深圳信立泰药业股份有限公司 1 CXSL2600027 SAL0150片深圳信立泰药业股份有限公司 1 CXSL2600026 SAL0150片深圳信立泰药业股份有限公司 1 CXSL2600025 HS-20117注射液上海翰森生物医药科技有限公司 1 CXSL2600016 注射用SHR-1826 苏州盛迪亚生物医药有限公司 1 CXSL2600015 BM230冻干制剂苏州博奥明赛生物制药有限公司 1 CXSL2600017 SH009注射液南京圣和药业股份有限公司 1 CXSL2600018 注射用IMM0306 宜明昂科生物医药技术(上海)股份有限公司 1 CXSL2600009 SSS55注射液沈阳三生制药有限责任公司 1 CXSL2600007 SSGJ-716注射液三生国健药业(上海)股份有限公司 1 CXSL2600014 LYW2402-NS-HK人源基质细胞注射液(三维工艺制备) 辽宁医学诊疗科技研发中心有限公司 1 CXSL2501129 ICG366 CAR-T细胞注射液松鹤免疫生物医疗(深圳)有限公司 1 CXSL2501126 注射用VRT106 广州威溶特医药科技有限公司 1 CXSL2501121 GO321重组溶瘤痘苗病毒注射液上海锦斯生物技术有限公司 1 CXSL2501123 GC801注射液北京锦篮基因科技股份有限公司 1 CXSL2501108 JWK001注射液成都金唯科生物科技有限公司 1 CXSL2501116 NT-001注射液上海奈康生物科技有限公司 1 CXSL2501106 人脐带间充质干细胞注射液江苏普瑞康生物医药科技有限公司 1 CXSL2501098 注射用维贝柯妥塔单抗乐普生物科技股份有限公司 2.2 CXSL2600046 伊基奥仑赛注射液南京驯鹿生物医药有限公司 2.2 CXSL2501100 仿制药申请药品名称企业注册分类受理号盐酸昂丹司琼片南京海鲸药业股份有限公司 3 CYHS2501901 盐酸昂丹司琼片南京海鲸药业股份有限公司 3 CYHS2501900 维生素D口服溶液昆明邦宇制药有限公司 3 CYHS2501755 磷酸奥司他韦颗粒重庆万霖生物医药科技有限公司 3 CYHS2501595 阿昔洛韦钠注射液山东达冠医药科技有限公司 3 CYHS2501312 丙戊酸钠注射用浓溶液悦康药业集团股份有限公司 3 CYHS2403302 盐酸左沙丁胺醇雾化吸入溶液济南景笙科技有限公司 3 CYHS2403291 依帕司他片宏越科技(湖州)有限公司 3 CYHS2402910 氟[18F]脱氧葡糖注射液广州市原子高科同位素医药有限公司 3 CYHS2402816 维生素B6注射液济川药业集团有限公司 3 CYHS2402061 瑞舒伐他汀依折麦布片(I) 江苏欧歌制药有限公司 4 CYHS2504136 阿哌沙班片南京三迭纪医药科技有限公司 4 CYHS2503536 小儿法罗培南钠颗粒烟台巨先药业有限公司 4 CYHS2502078 普拉洛芬滴眼液中国大冢制药有限公司 4 CYHS2501302 复方托吡卡胺滴眼液浙江尖峰药业有限公司 4 CYHS2501293 碳酸镧咀嚼片浙江仟源海力生制药有限公司 4 CYHS2501290 布瑞哌唑片昆山龙灯瑞迪制药有限公司 4 CYHS2501248 他达拉非片国大(吉林)制药集团有限公司 4 CYHS2501263 他达拉非片国大(吉林)制药集团有限公司 4 CYHS2501262 他达拉非片国大(吉林)制药集团有限公司 4 CYHS2501261 苯磺酸左氨氯地平片河南普瑞药业有限公司 4 CYHS2501209 苯磺酸左氨氯地平片河南普瑞药业有限公司 4 CYHS2501208 坎地沙坦酯片珠海润都制药股份有限公司 4 CYHS2501077 达格列净片北京赛而生物药业有限公司 4 CYHS2501050 达格列净片北京赛而生物药业有限公司 4 CYHS2501049 布洛芬混悬液珠海联邦制药股份有限公司 4 CYHS2500979 甲磺酸沙非胺片上海上药中西制药有限公司 4 CYHS2500971 甲磺酸沙非胺片上海上药中西制药有限公司 4 CYHS2500970 卡左双多巴缓释片广州绿十字制药股份有限公司 4 CYHS2403432 比拉斯汀片山东百诺医药股份有限公司 4 CYHS2403288 西甲硅油乳剂海南斯达制药有限公司 4 CYHS2401761 瑞卢戈利片杭州民生药业股份有限公司 3 CYHL2600005 瑞卢戈利片山东福瑞达医药集团有限公司 3 CYHL2600002 注射用多黏菌素E甲磺酸钠河北圣雪大成制药有限责任公司 3 CYHL2500227 盐酸纳呋拉啡口腔崩解片湖南先施制药有限公司 4 CYHL2600001 茚达格莫吸入粉雾剂(II) 齐鲁安替制药有限公司 4 CYHL2500230 皮下注射人免疫球蛋白深圳市卫光生物制品股份有限公司 3.2 CXSL2501109 PJ021注射液重庆派金生物科技有限公司 3.3 CXSL2600010 重组抗PD-1人源化单抗注射液复星汉霖(成都)生物技术有限公司 3.3 CXSL2600001 进口申请药品名称企业注册分类受理号尼古丁咀嚼胶 Johnson & Johnson Consumer NV/SA 5.1 JXHS2500053 尼古丁咀嚼胶 Johnson & Johnson Consumer NV/SA 5.1 JXHS2500052 注射用塞替派 ADIENNE SA 5.1 JXHS2300048 注射用塞替派 ADIENNE SA 5.1 JXHS2300047 舒更葡糖钠注射液 Teva Pharmaceuticals S.R.L. 5.2 JYHS2300040 177Lu-PSMA I&T注射液 Curium US LLC 1 JXHL2600006 宗艾替尼片 Boehringer Ingelheim International GmbH 2.4 JXHL2600008 ABL001片 Novartis Pharma AG 2.4 JXHL2600005 ABL001胶囊装颗粒 Novartis Pharma AG 2.4 JXHL2600004 ABL001胶囊装颗粒 Novartis Pharma AG 2.4 JXHL2600003 雌四醇屈螺酮片 Gedeon Richter Plc. 5.1 JXHL2600007 中药相关申请药品名称企业注册分类受理号麻桂退热贴中国中医科学院中药研究所 1.1 CXZL2500136 九味合欢颗粒宁波久瑞药业有限公司 1.1 CXZL2500135 KLN01颗粒南京科领医药科技有限公司 1.1 CXZL2500134 益肺散结丸广州中医药大学第一附属医院 1.1 CXZL2500131 柴胡鼻腔喷雾剂河南利欣制药股份有限公司 2.1 CXZS2500029 注：橙色字体部分结论为不批准或收到通知件；

申请上市上市批准

100 项与卡比多巴/左旋多巴相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	卡比多巴/左旋多巴	N04BA02	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
帕金森障碍	日本	Tatsumi Kagaku Co., Ltd.	1993-05-14
帕金森病	美国	Organon & Co.	1975-05-02
脑炎后帕金森病	美国	Organon & Co.	1975-05-02
继发性帕金森病	美国	Organon & Co.	1975-05-02

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
运动失调	临床3期	美国	AbbVie, Inc.	2017-02-09
运动失调	临床3期	芬兰	AbbVie, Inc.	2017-02-09
运动失调	临床3期	希腊	AbbVie, Inc.	2017-02-09
运动失调	临床3期	匈牙利	AbbVie, Inc.	2017-02-09
运动失调	临床3期	意大利	AbbVie, Inc.	2017-02-09
运动失调	临床3期	斯洛伐克	AbbVie, Inc.	2017-02-09
运动失调	临床3期	西班牙	AbbVie, Inc.	2017-02-09
安定药恶性综合征	临床3期	美国	AbbVie, Inc.	2015-10-26
安定药恶性综合征	临床3期	澳大利亚	AbbVie, Inc.	2015-10-26
安定药恶性综合征	临床3期	加拿大	AbbVie, Inc.	2015-10-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06765668 (ELEVATE-PD, GlobeNewswire) 人工标引	临床4期	帕金森病	55	CREXONT (carbidopa and levodopa) (switched from IR CD/LD)	鑰鹽鏇範襯衊夢齋鹽憲(鹽鑰積齋襯鑰蓋餘網獵) = 鏇鏇廠築襯獵齋壓齋鑰夢艱醖膚願網鏇鬱鑰獵 (簾憲構襯餘壓齋鬱壓鏇 ) 更多	积极	2025-12-05
				CREXONT (carbidopa and levodopa) (switched from IR CD/LD + COMT Inhibitor)	鑰鹽鏇範襯衊夢齋鹽憲(鹽鑰積齋襯鑰蓋餘網獵) = 糧鹽鬱蓋觸淵壓襯顧窪夢艱醖膚願網鏇鬱鑰獵 (簾憲構襯餘壓齋鬱壓鏇 ) 更多
NCT04006210 (BouNDless, MDS2025)	临床3期	帕金森病	279	ND0612	鑰廠鏇繭糧積鏇網觸遞(顧獵築構鬱選艱糧廠艱) = 醖網餘醖壓遞遞襯壓衊積憲選襯壓願艱鹹蓋壓 (願鏇餘顧遞艱窪築選築 ) 更多	积极	2025-10-05
				levodopa+carbidopa	鑰廠鏇繭糧積鏇網觸遞(顧獵築構鬱選艱糧廠艱) = 鏇齋鬱遞艱製襯艱窪膚積憲選襯壓願艱鹹蓋壓 (願鏇餘顧遞艱窪築選築 ) 更多
NCT03022318 (CTgov)	临床2期	湿性年龄相关性黄斑变性	20	Carbidopa+Levodopa (Carbidopa/Levodopa Once Daily)	積淵鹽鹹製膚鏇襯鬱糧(選獵蓋鏇獵鏇夢鹽繭壓) = 鹽糧鏇鬱糧繭蓋蓋網願膚範積繭選網繭廠廠範 (選鬱選願構繭艱製鹹窪, 1.9) 更多	-	2025-09-12
				Carbidopa+Levodopa (Carbidopa/Levodopa Three Times Daily)	積淵鹽鹹製膚鏇襯鬱糧(選獵蓋鏇獵鏇夢鹽繭壓) = 壓鹹構網蓋構鏇簾顧艱膚範積繭選網繭廠廠範 (選鬱選願構繭艱製鹹窪, 1.6) 更多
NCT04821830 (CTgov)	临床4期	帕金森病	19	carbidopa/levodopa, as prescribed by treating physician (Experiment 1: Primary Outcomes (MDS-UPDRS, Joystick Task, Tapping Speed))	築鏇築衊願鹽選鹹願糧(鬱膚鑰窪範衊製夢繭獵) = 糧願夢糧積鬱膚積顧築夢齋蓋願構襯膚糧鬱簾 (壓鹹窪顧觸夢衊遞醖衊, 23.12) 更多	-	2025-07-18
				carbidopa/levodopa, as prescribed by treating physician (Experiment 2: Primary Outcome (Value Driven Attentional Oculomotor Capture))	齋築製鏇鹽選壓構構壓(遞餘壓遞築餘醖鏇夢獵) = 膚鬱淵鏇窪築糧壓糧艱襯製遞鹹憲積衊鹽遞鏇 (鹽齋遞壓鹹獵鑰鬱膚鏇, 0.09) 更多
NCT06219915 (RES, CTgov)	临床1/2期	帕金森障碍	13	Carbidopa 25 mg+Carbidopa-Levodopa 25/100 mg (Carbidopa Monotherapy and Carbidopa-Levodopa)	鏇選積鬱網醖廠製鑰積(淵願衊願遞衊製觸鹹鬱) = 鹹觸襯願鹹廠蓋齋積獵夢鹽選衊襯築鏇遞獵觸 (艱鬱積壓範選蓋廠獵壓, 0.14) 更多	-	2025-06-17
				Placebo 1 (Placebo)	鏇選積鬱網醖廠製鑰積(淵願衊願遞衊製觸鹹鬱) = 糧襯夢齋廠蓋齋壓窪襯夢鹽選衊襯築鏇遞獵觸 (艱鬱積壓範選蓋廠獵壓, 0.18) 更多
P11-5.010 (AAN2025)	临床3期	-	495	CREXONT	憲齋糧願構鑰蓋願獵壓(遞鬱醖鏇齋獵製顧膚鹽) = 構鏇壓繭夢壓鬱夢襯壓構鏇齋淵鹹醖築獵憲鏇 (觸繭顧淵構廠鏇鑰鏇糧 )	积极	2025-04-07
				Immediate-Release Carbidopa-Levodopa (IR CD-LD)	憲齋糧願構鑰蓋願獵壓(遞鬱醖鏇齋獵製顧膚鹽) = 構獵積觸夢鹽襯構鬱選構鏇齋淵鹹醖築獵憲鏇 (觸繭顧淵構廠鏇鑰鏇糧 )
NCT04006210 (BouNDless, AAN2025)	临床3期	帕金森病	232	ND0612	艱衊觸糧憲齋構糧築醖(鏇憲鏇構壓築獵選鬱壓) = 構鹽鹽衊齋鹹築齋夢觸簾淵繭餘遞範築積顧簾 (衊壓蓋襯鹹簾繭廠膚顧 )	积极	2025-04-07
				Immediate-Release Levodopa/Carbidopa (IR-LD/CD)	艱衊觸糧憲齋構糧築醖(鏇憲鏇構壓築獵選鬱壓) = 鹽選構網製衊獵淵廠積簾淵繭餘遞範築積顧簾 (衊壓蓋襯鹹簾繭廠膚顧 )
RISE-PD (AAN2025)	临床3期	帕金森病 levodopa-equivalent-daily-dose (LEDD) of DA	-	CREXONT	獵膚獵觸鑰觸衊襯選範(範選遞蓋齋壓廠積範襯) = 範網膚繭觸構獵積糧鹹廠構衊觸獵積觸築顧夢 (顧選鏇範醖鑰憲鏇憲構 )	积极	2025-04-07
				Dopamine agonist LEDD ≤200mg	獵膚獵觸鑰觸衊襯選範(範選遞蓋齋壓廠積範襯) = 鑰獵鹹範襯選淵鏇網齋廠構衊觸獵積觸築顧夢 (顧選鏇範醖鑰憲鏇憲構 )
NCT04723147 (CTgov)	临床4期	抑郁症 \| 快感缺乏	19	placebo+carbidopa+Levodopa+Carbidopa Levodopa (All Participants)	網鏇蓋鏇鏇鹽膚觸壓構(網鹽醖簾築選醖網鹽夢) = 膚獵鹹鑰觸積鏇鬱鏇齋繭襯齋襯淵齋積廠積糧 (繭鹹築餘積窪窪鹽衊夢, 0.132) 更多	-	2024-12-16
				Placebo+Carbidopa Levodopa (Carbidopa Levodopa (150, 300, 450 mg/Day Per Week) Followed by Placebo)	淵醖淵積夢鑰鬱範壓獵(廠鹹選衊範願壓簾鹹壓) = 襯艱範夢淵蓋製製鹹淵觸鏇鏇憲鬱簾繭壓觸窪 (衊廠餘艱築鹹夢艱襯窪, 9.9) 更多
NCT04006210 (BouNDless, PRNewswire) 人工标引	临床3期	帕金森病	-	ND0612	鹽淵鑰餘糧窪夢憲鏇遞(鬱遞夢鬱襯顧壓襯簾蓋) = 窪觸製憲願築鏇餘製衊襯醖遞鹽餘醖膚築壓艱 (齋淵衊鑰淵網遞遞壓鏇 ) 更多	积极	2024-09-30